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Completion of the template is the responsibility of the laboratory performing the biomarker testing and/or providing the interpretation. When both testing and interpretation are performed elsewhere (eg, a reference laboratory), synoptic reporting of the results by the laboratory submitting the tissue for testing is also encouraged to ensure that all information is included in the patient's medical record and thus readily available to the treating clinical team. This template is not required for accreditation purposes.
CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL)
Select a single response unless otherwise indicated. 
+ SPECIMEN TYPE

Explanatory Notes
A. Introduction Somatic mutation in the rearranged variable regions of immunoglobulin heavy chains (IgVH) has been reported to be of prognostic importance since 1999. 1, 2 Patients with IgVH unmutated genes have a more aggressive disease and are more resistant to therapy than those with mutated IgVH genes. Most researchers defined unmutated IgVH based on 98% or more homology to reference and mutated IgVH with less than or equal to 97% homology to reference. 3 Determining IgVH mutations requires specific equipment and is laborious, expensive, and timeconsuming. Due to all these limitations, surrogate markers including CD38 and ZAP-70, with the similar prognostic value as IgVH mutation status are more widely used.
Detection of immunoglobulin VH3-21 usage by sequencing of IgH rearrangements has been associated with poor outcome in CLL and should be reported when detected by IgH sequencing.
B. Prognosis in CLL FISH
Del 11q contains several tumor suppressor genes including ATM. 4, 5 This gene is associated with cell cycle regulation and p53 pathway activation. BIRC3, which is also in the deleted region of interest, is a candidate gene that may also play a role in CLL pathobiology. Del 11q is associated with younger age and poor prognosis.
Del 13q is often seen as a sole abnormality in CLL. 4, 5 It is associated with a favorable prognosis. Several genes and micro-RNAs (mRNA) have been suggested as candidate genes in these cases of CLL. Del 17p is thought to affect the TP53 gene, a key regulator of cell cycle. 4, 5 Other deleted genes may also play a role. Patients with del17p will often have other genetic abnormalities and other poor prognosis markers.
Trisomy 12 (+12) affects CLL by an unknown mechanism. 4, 5 Patients with trisomy 12 have a good response to treatment. Some additional trisomies (+19, +19) are seen in association with trisomy 12.
Marker
Approx 
C. CD38 Expression
CD38 is a 45 KDa transmembrane glycoprotein that was the first maker found to correlate with IgVH mutation. 2 Patients with CD38-positive cells have unmutated IgVH genes and higher need for chemotherapy as well as shorter overall survival. However, subsequent studies showed that association between mutation status and CD38 expression level was not absolute and that CD38 expression should be considered as an independent prognostic marker in CLL.
6 CD38 expression is determined by flow cytometry. A 30% cutoff level is generally used empirically to classify CD38-positive and CD38-negative patients; individual laboratories should determine their own criteria for calling CD38-positive and CD38-negative cases, and specific laboratory cut-offs should be described in the methods section above.
1,6 CD38 expression may vary over time and may show a bimodal expression profile. 
D. ZAP-70 Expression
Comparative microarray studies performed on cases of CLL with mutated and unmutated IgVH genes showed differential expression of gene encoding for zeta-associated protein of 70 kDa (ZAP-70). 7 Zap-70 is normally There is inherent laboratory-to-laboratory variability in ZAP-70 testing due to the following: different antibody clones used (variable antigen affinity), different conjugated fluorochromes (variable intensity), variable methods of cell permeabilization (for intracellular staining), variable staining procedures, variable gating procedures, and variable reporting methods. Moreover, ZAP-70 is a labile protein; most consensus guidelines recommend ZAP-70 testing within 24 hours of sample collection. Laboratories should establish firm gating criteria for sample collection and determine reference populations at the point of method validation of their assay to ensure optimal interassay precision. Different gating strategies are discussed extensively in a prior multicenter international harmonization study. 
